Spinal muscular atrophy
暂无分享,去创建一个
[1] K. Eichinger,et al. Combination therapy with nusinersen and AVXS-101 in SMA type 1 , 2019, Neurology.
[2] J. Shefner,et al. Nusinersen in later-onset spinal muscular atrophy , 2019, Neurology.
[3] E. Tizzano,et al. Perspectives in genetic counseling for spinal muscular atrophy in the new therapeutic era: early pre-symptomatic intervention and test in minors , 2019, European Journal of Human Genetics.
[4] L. Servais,et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1 , 2018, Neurology.
[5] R. Finkel,et al. Treatment Algorithm for Infants Diagnosed with Spinal Muscular Atrophy through Newborn Screening , 2018, Journal of neuromuscular diseases.
[6] R. J. Ramamurthi,et al. Nusinersen versus Sham Control in Infantile‐Onset Spinal Muscular Atrophy , 2017, The New England journal of medicine.
[7] Brian K. Kaspar,et al. Single‐Dose Gene‐Replacement Therapy for Spinal Muscular Atrophy , 2017, The New England journal of medicine.
[8] R. Finkel,et al. Spinal muscular atrophy: A changing phenotype beyond the clinical trials , 2017, Neuromuscular Disorders.
[9] W. Chung,et al. Observational study of spinal muscular atrophy type I and implications for clinical trials , 2014, Neurology.